Your browser doesn't support javascript.
loading
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.
Wheeler, David A; Takebe, Naoko; Hinoue, Toshinori; Hoadley, Katherine A; Cardenas, Maria F; Hamilton, Alina M; Laird, Peter W; Wang, Linghua; Johnson, Adrienne; Dewal, Ninad; Miller, Vincent; Piñeyro, David; Castro de Moura, Manuel; Esteller, Manel; Shen, Hui; Zenklusen, Jean Claude; Tarnuzzer, Roy; McShane, Lisa M; Tricoli, James V; Williams, Paul M; Lubensky, Irina; O'Sullivan-Coyne, Geraldine; Kohn, Elise C; Little, Richard F; White, Jeffrey; Malik, Shakun; Harris, Lyndsay; Weil, Carol; Chen, Alice P; Karlovich, Chris; Rodgers, Brian; Shankar, Lalitha; Jacobs, Paula; Nolan, Tracy; Hu, Jianhong; Muzny, Donna M; Doddapaneni, Harshavardhan; Korchina, Viktoriya; Gastier-Foster, Julie; Bowen, Jay; Leraas, Kristen; Edmondson, Elijah F; Doroshow, James H; Conley, Barbara A; Ivy, S Percy; Staudt, Louis M.
Afiliação
  • Wheeler DA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Hinoue T; Van Andel Institute, Grand Rapids, MI 49503, USA.
  • Hoadley KA; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Cardenas MF; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Hamilton AM; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Laird PW; Van Andel Institute, Grand Rapids, MI 49503, USA.
  • Wang L; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Johnson A; Foundation Medicine Inc, Cambridge, MA 02141, USA.
  • Dewal N; Foundation Medicine Inc, Cambridge, MA 02141, USA.
  • Miller V; Foundation Medicine Inc, Cambridge, MA 02141, USA.
  • Piñeyro D; Josep Carreras Leukaemia Research Institute, Badalona, 08916 Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain.
  • Castro de Moura M; Josep Carreras Leukaemia Research Institute, Badalona, 08916 Barcelona, Catalonia, Spain.
  • Esteller M; Josep Carreras Leukaemia Research Institute, Badalona, 08916 Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029 Madrid, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain; Physiological Sciences Department,
  • Shen H; Van Andel Institute, Grand Rapids, MI 49503, USA.
  • Zenklusen JC; Center for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Tarnuzzer R; Center for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA.
  • McShane LM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Lubensky I; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • O'Sullivan-Coyne G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Kohn EC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Little RF; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • White J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Malik S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Harris L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Weil C; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Karlovich C; Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Rodgers B; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Shankar L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Jacobs P; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Nolan T; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
  • Hu J; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Muzny DM; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Doddapaneni H; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Korchina V; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Gastier-Foster J; Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Bowen J; Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Leraas K; Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Edmondson EF; Pathology and Histology Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21701, USA.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
  • Staudt LM; Center for Cancer Genomics, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: lstaudt@mail.nih.gov.
Cancer Cell ; 39(1): 38-53.e7, 2021 01 11.
Article em En | MEDLINE | ID: mdl-33217343
ABSTRACT
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories-DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis-with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Variação Genética / Genômica / Redes Reguladoras de Genes / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Variação Genética / Genômica / Redes Reguladoras de Genes / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos